Literature DB >> 3778208

The role of modified neck dissection in the treatment of cutaneous melanoma of the head and neck.

R M Byers.   

Abstract

One hundred eighty-one patients were treated with a modified neck dissection for suspected or proved metastatic melanoma during a ten-year period. The overall failure rate in the neck was 16%. Eighty-three percent of the patients with neck recurrence died of disseminated disease. A modified neck dissection that preserves important functional and cosmetic structures but does not compromise cancer control seemed to be appropriate treatment for actual or suspected melanoma metastatic to cervical nodes.

Entities:  

Mesh:

Year:  1986        PMID: 3778208     DOI: 10.1001/archsurg.121.11.1338

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  6 in total

Review 1.  Melanoma of the head and neck.

Authors:  Terry A Day; Joshua D Hornig; Anand K Sharma; Frank Brescia; M Boyd Gillespie; Deanne Lathers
Journal:  Curr Treat Options Oncol       Date:  2005-01

2.  Neck dissection for cutaneous malignant melanoma.

Authors:  C J O'Brien; M P Gianoutsos; M J Morgan
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

3.  Loco-regional control after postoperative radiotherapy for patients with regional nodal metastases from melanoma.

Authors:  Carlos Conill; Izaskun Valduvieco; Josep Domingo-Domènech; Pedro Arguis; Sergi Vidal-Sicart; Antonio Vilalta
Journal:  Clin Transl Oncol       Date:  2009-10       Impact factor: 3.405

4.  Adjuvant radiation therapy after axillary lymphadenectomy for metastatic melanoma: toxicity and local control.

Authors:  E A Strom; M I Ross
Journal:  Ann Surg Oncol       Date:  1995-09       Impact factor: 5.344

5.  Role of radiotherapy in melanoma management.

Authors:  Primoz Strojan
Journal:  Radiol Oncol       Date:  2010-03-18       Impact factor: 2.991

6.  Adjuvant radiation therapy in metastatic lymph nodes from melanoma.

Authors:  Jean-Emmanuel Bibault; Sylvain Dewas; Xavier Mirabel; Laurent Mortier; Nicolas Penel; Luc Vanseymortier; Eric Lartigau
Journal:  Radiat Oncol       Date:  2011-02-06       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.